Despite the fact that the multiple sclerosis GWAS literature does not highlight GPR65, sphingolipid metabolism has emerged as a therapeutic target for MS via the drug fingolimod, a sphingosine analog that alters immune cell trafficking and is now in clinical use (Brinkmann et al. 2010). This evidence concerns the gene GPR65 and myeloid sarcoma.